Lademirsen

SAR339375 · Genzyme, a Sanofi Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lademirsen, covering 2023-10-23 to 2023-10-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of Lademirsen (SAR339375) in Patients With Alport Syndrome [Phase 2]